Promising myeloma combo trial halted early – what we know
NCT ID NCT03622775
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether two drugs, daratumumab and pomalidomide, could help control multiple myeloma that came back after a stem cell transplant. It involved 13 adults whose cancer had relapsed. The goal was to see if the combination could lead to complete remission and delay the cancer's return. The trial was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood cancer transplant study tests safer GVHD prevention
- New hope for hard-to-treat myeloma: three-drug combo enters phase 2 trial
- Stem cell transplant study seeks best way to prevent immune attack
- New immune cell therapy takes on Hard-to-Treat myeloma
- New combo tackles resistant myeloma in early trial
- New transplant recipe may tame Graft-Versus-Host disease in blood cancer patients